Cadila Healthcare is one of the top three in gynaecology, respiratory, pain management, CVS and dermatology.
and earnings ahead. On the high base, we expect 8 percent and 9 percent CAGRs over FY18-21 in revenue and earnings respectively.
The company expects 40-50 launches annually and is focusing on vaccines and biologics â€“ which could be future growth drivers.
It has strong ANDA pipeline in the US, with 144 filings awaiting approval of which 60+ are Para IV. It launched 20 products in the year,
including g Lialda and gTamiflu and received 77 approvals in FY18, bringing cumulative filings/approvals to 330/186.
The company has recently announced it is considering fund raising proposals of up to Rs 10,000 Cr via QIP & up to Rs 5,000 cr via FCCBs.